Responses
Clinical/translational cancer immunotherapy
Original research
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.